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158The inﬂuence of gender on patency rates after iliac
artery stenting
Beate Bechter-Hugl, MD,a Jürgen Falkensammer, MD,a,b Olaf Gorny, MD,a Andreas Greiner, MD,a,c
Andreas Chemelli, MD,d and Gustav Fraedrich, MD,a Innsbruck and Vienna, Austria; and Aachen, Germany
Objective: The purpose of this study was to investigate the inﬂuence of gender on the long-term outcome after iliac artery
stenting and to assess gender-speciﬁc differences of the inﬂuence of risk factors on treatment success and patency rates.
Methods: Between January 2000 and December 2006, 404 percutaneous transluminal angioplasties with primary stent
deployment for symptomatic iliac artery occlusive disease were performed at our center. These included 128 interventions
in women and 276 interventions in men.
Results: Whereas average age was signiﬁcantly higher (65.9 6 12.9 years; P [ .007) and arterial hypertension more
frequent (60.9% vs 49.3%; P[ .032) in women, hyperuricemia (7.0% vs 14.1%; P[ .047) and a positive smoking status
(61.7% vs 74.3%; P[ .014) were more frequently observed in men. Fontaine stage was more advanced (stages III and IV)
in women than in men (P [ .028; P < .001). Technical success was 97.7% in women and 99.3% in men. Overall
complication rate was higher in women compared with men (P[ .002), mostly caused by access site hematomas (4.7% vs
0.4%) and pseudoaneurysms (8.6% vs 2.5%). Patients were followed up for 45.0 6 33.3 months. Restenosis developed in
16.8% of cases in women and in 14.6% of cases in men and was treated in 73.7% by an endovascular approach. Primary
patency rates at 1, 3, 5, and 7 years were 90.3%, 77.2%, 60.2%, and 46.4% in women and 89.9%, 71.5%, 63.6%, and 59.7%
in men, respectively (P [ .524; log-rank, .406). Secondary patency rates were 97.2%, 91%, 81.5%, and 70.3% in women
and 97.1%, 89.1%, 82.6%, and 78% in men, respectively (P[ .959; log-rank, .003). Multivariate analysis identiﬁed lower
age as the only independent risk factor for recurrent disease in both groups. Age-deﬁned subgroup analysis showed a
restenosis/reocclusion rate of 23.9% in men and 22.1% in women older than 63.5 years (P[ .861) but 32.1% in men and
49.1% in women younger than that (P [ .034).
Conclusions: Our data suggest that although women are older and present with a more advanced stage of peripheral
arterial occlusive disease, endovascular therapy is equally effective irrespective of gender. Surprisingly, the subgroup of
young female patients had a speciﬁcally poor outcome. (J Vasc Surg 2014;59:1588-96.)The annual prevalence of peripheral arterial occlusive
disease (PAOD) in the Western community varies between
10% and 30%, depending on the presence of risk factors.
Population-based studies showed that the disease does
almost equally affect women and men, and some studies
have even reported a predominance of women with critical
limb ischemia (CLI).1 About one third of PAOD lesions
affect the aortoiliac segment.2 According to the TransAt-
lantic Inter-Society Consensus (TASC) II, an endovascular
intervention is the standard of care for the treatment of pa-
tients with TASC type A and preferably also for patients
with TASC type B atherosclerotic lesions of the iliac artery.
Although surgical treatment is generally recommended for
TASC II type C and type D lesions, recent advancements
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8have extended the indications for endovascular treatment,
especially in patients who are poor candidates for a major
operation. The broader application of endovascular therapy
is supported by the fact that stenting of the vessel has
consistently been shown to provide excellent immediate
and satisfactory long-term results.3-5 Several risk factors,
such as poor runoff, presence of CLI, long iliac lesions, iliac
artery occlusion, involvement of the external iliac artery
(EIA), and diabetes or renal failure, are associated with
reduced patency rates.6-9 Data on the impact of other
risk factors, including gender, on long-term outcome are
inconsistent.6-9 However, most previous investigations
with the exception of one report did not speciﬁcally stratify
for gender.6
This study was designed to investigate the inﬂuence of
gender on the long-term outcome after iliac artery stenting
and to assess gender-speciﬁc differences of the inﬂuence of
risk factors on treatment success and patency rates.METHODS
The study was approved by the Ethics Committee of
the Medical University Innsbruck.
Patients. Between January 2000 and December 2006,
a total of 463 iliac artery revascularizations were performed
in 396 patients at our center. These included 52 open iliac
reconstructions (eight women), seven percutaneous trans-
luminal angioplasties (PTAs; two women), and a total of
Table I. Fontaine Classiﬁcation25
Stage
I Asymptomatic
II Intermittent claudication
IIa Claudication at a distance of more than 200 meters
IIb Claudication at a distance of less than 200 meters
III Rest pain
IV Necrosis or gangrene of the limb
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iliac artery reconstructions in women were done by open
surgery and 92.8% by stenting; this ratio was 13.5% for
open and 84.9% for stenting in men (P ¼ .0015). For
the current analysis, the 404 cases of iliac artery stenting
were stratiﬁed for gender and include 128 interventions
in women and 276 interventions in men. Indications for
treatment were the presence of symptomatic PAOD of
Fontaine stage II or higher (Table I) and the concomi-
tant presence of a hemodynamically signiﬁcant lesion
(deﬁned as a greater than 60% reduction of arterial diam-
eter). Patients who had undergone previous surgical or
endovascular arterial revascularization (PTA or stenting)
were not included for this analysis.
Preinterventional diagnostic assessment consisted of a
clinical examination, assessment of the ankle-brachial in-
dex, and standardized treadmill test at 3 km/h and 12%
incline. Duplex ultrasound of the iliac and lower limb ar-
teries was performed to deﬁne the iliac artery stenosis and
to screen for multilevel disease. In case of a pathologic
ﬁnding, magnetic resonance angiography was performed.
For all patients, the TASC II classiﬁcation was used.1
Follow-up investigations included a clinical evaluation,
ankle-brachial index assessment, and duplex ultrasound
investigation of the target vessels at 3, 6, and 12 months
after the intervention and once every year thereafter. Ultra-
sound scans during follow-up were performed to exclude a
restenosis or vessel occlusion. Thereby even asymptomatic
restenoses or occlusions were detected. A lumen reduction
of more than 60% of diameter detected by duplex ultra-
sound was considered a signiﬁcant restenosis, deﬁned as
peak velocity ratio >2.4.
Stent technique and treatment. For endovascular in-
terventions, all patients were referred to the interventional
radiologist. By retrograde ipsilateral or contralateral
femoral artery puncture, 6F to 8F sheaths and 0.035-inch
hydrophilic guidewires were placed. A bilateral approach
was used for patients requiring bilateral iliac artery stenting.
Predilation with an undersized balloon before stent
deployment was performed only if the lesion could not be
passed with the stent delivery catheter to minimize the risk
of distal embolization of atherosclerotic debris. The choice
of which balloon diameters were used was determined ac-
cording to the diameter of the reference vessel in the vi-
cinity of the lesion. The diameter of a balloon-expandable
stent was sized to the actual normal artery diameter to
avoid risk of rupture of the artery. A self-expanding stent
was oversized intentionally by 10% to 15% in relation to the
original arterial diameter. Postdilation results aimed at less
than 10% residual stenosis. In selected cases with multilevel
disease affecting the femoral bifurcation or the superﬁcial
femoral artery, a surgical endarterectomy in combination
with patch angioplasty or femoropopliteal bypass was per-
formed. With regard to the endovascular technique,
balloon-expandable stents (Palmaz stent; Cordis/Johnson
& Johnson, Bridgewater, NJ; Express stent, Boston Sci-
entiﬁc, Natick, Mass) were used for severely calciﬁed and
ostial lesions. In less calciﬁed or tortuous arteries, self-expandable stents (Wallstent; Boston Scientiﬁc, Natick,
Mass; and S.M.A.R.T. stent; Cordis/Johnson & Johnson,
Bridgewater, NJ) were preferred. A kissing stent technique
was applied in cases that showed involvement of the aortic
bifurcation. During intervention, all patients received a
bolus of 5000 IU of unfractionated heparin followed by
intravenous infusion of 500 IU/h for 24 hours. Patients
receiving oral anticoagulation before intervention received
a peri-interventional bridging therapy with low-molecular-
weight heparin, and anticoagulation was resumed after-
ward. In these cases, 100 mg of acetylsalicylic acid was
administered for 3 months after the intervention. In pa-
tients who were already taking clopidogrel before the
intervention, this medication was continued afterward. All
other patients received acetylsalicylic acid (100 mg/d) as
permanent therapy.
Statistical analysis. Statistical analysis was performed
with SPSS 15.0 for Windows (SPSS Inc, Chicago, Ill).
The patient population was stratiﬁed by gender. Distribu-
tion of continuous variables was assessed by the
Kolmogorov-Smirnov test. Descriptive statistics (mean,
standard deviation, range) were applied to acquired data,
and t test or Wilcoxon signed rank tests were used for
comparison of continuous variables, as applicable. Cate-
gorical variables were expressed as frequencies and per-
centages, and differences between groups were investigated
by the Pearson c2 and Fisher exact tests. P values < .05
were considered signiﬁcant. Univariate and multivariate
Cox regression analysis was performed to identify risk fac-
tors associated with target lesion patency. Follow-up data
were plotted as Kaplan-Meier life-table analysis, and dif-
ferences between groups were assessed by application of
the log-rank test.
RESULTS
Demographics, clinical data, and anatomic status.
During the assessed time period, a total of 404 primary iliac
artery stent-PTAs in 337 patients were performed. Case-
related data are summarized in Table II. Cardiovascular
risk factors were deﬁned as previously described.10
With regard to comorbidities, peri-interventional medi-
cation, and most of the cardiovascular risk factors, no sig-
niﬁcant differences between genders were found.
However, women were signiﬁcantly older (P ¼ .007),
and arterial hypertension was more prevalent (P ¼ .032).
In men, hyperuricemia and a positive smoking status
were observed more frequently (P ¼ .047 and P ¼ .014,
Table II. Demographics, cardiovascular risk factors, comorbidities, clinical and anatomic status, and prestent and
poststent medication
Variablea All (404 interventions) Women (128 interventions) Men (276 interventions) P
Age, years 63.5 6 11.5 (35.7-95.1) 65.9 6 12.9 (35.9-89.2) 62.4 6 10.7 (35.7-95.1) .007
Cardiovascular risk factors
Arterial hypertension 214 (53.0) 78 (60.9) 136 (49.3) .032
Diabetes mellitus 99 (24.5) 28 (21.9) 71 (25.7) .456
Hyperlipidemia 222 (55.0) 69 (53.9) 153 (55.4) .830
Hyperuricemia 48 (11.9) 9 (7.0) 39 (14.1) .047
Obesity 72 (17.8) 26 (20.3) 46 (16.7) .403
Smoking history
Current 241 (59.7) 69 (53.9) 172 (62.3) .127
Current or previous 284 (70.3) 79 (61.7) 205 (74.3) .014
Comorbidities
CHD 114 (28.2) 39 (30.5) 75 (27.2) .553
Previous MI 61 (15.1) 18 (14.1) 43 (15.6) .766
Previous TIA or stroke 33 (8.2) 11 (8.6) 22 (8.0) .846
COPD 65 (16.1) 19 (14.8) 46 (16.7) .771
Chronic renal insufﬁciency 47 (11.6) 13 (10.2) 34 (12.3) .618
Ankle-brachial index at baseline 0.66 6 0.28 (0.00-1.30) 0.62 6 0.30 (0.00-1.30) 0.67 6 0.26 (0.00-1.30) .132
Fontaine stage
II 307 (76) 76 (59.4) 231 (83.7) <.001
III 32 (7.9) 16 (12.5) 16 (5.8) .028
IV 65 (16.1) 36 (28.1) 29 (10.5) <.001
TASC
A 221 (54.7) 62 (48.4) 159 (57.6) .087
B 133 (32.9) 40 (31.3) 93 (33.7) .651
C 13 (3.2) 6 (4.7) 7 (2.5) .362
D 34 (8.4) 17 (13.3) 17 (6.2) .021
Prestent medication
Antiaggregation 203 (50.2) 61 (47.7) 142 (51.4) .522
ASA 182 (45.0) 58 (45.3) 124 (44.9) 1.000
Clopidogrel 9 (2.2) 2 (1.6) 7 (2.5) .725
ASA þ clopidogrel 12 (3.0) 1 (0.8) 11 (4.0) .114
Acenocoumarol 30 (7.4) 9 (7.0) 21 (7.6) 1.000
Statin 40 (9.9) 8 (6.3) 32 (11.6) .108
Poststent medication
Antiaggregation 379 (93.8) 122 (95.3) 257 (93.1) .508
ASA 332 (82.2) 98 (76.7) 234 (84.8) .051
Clopidogrel 27 (6.7) 13 (10.2) 14 (5.1) .084
ASA þ clopidogrel 22 (5.4) 9 (7.0) 13 (4.7) .352
Acenocoumarol 30 (7.4) 9 (7.0) 21 (7.6) 1.000
Statin 167 (41.3) 50 (39.1) 117 (42.4) .587
ASA, Acetylsalicylic acid; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease;MI, myocardial infarction; TASC, TransAtlantic Inter-
Society Consensus; TIA, transient ischemic attack.
aData are expressed as mean 6 standard deviation (range) or number (%).
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of cases received an antiplatelet therapy, which must be
attributed to the fact that a substantial number of patients
were referred to our center from different medical facilities
or private practices within days before treatment. After the
intervention, 93.8% of cases were treated with antiaggrega-
tory medication. In a minority of our cases (7.4%), a preex-
isting medical condition required the continuation of
antithrombotic therapy with acenocoumarol. Fontaine
stage was more advanced in women; stages III and IV
were present in 12.5% and 28.1% compared with 5.8%
and 10.5% in men (P ¼ .028 and P < .001, respectively).
In contrast, Fontaine stage II was signiﬁcantly more prev-
alent in men compared with women (83.7% vs 59.4%;
P < .001). However, univariate analysis did not show a sig-
niﬁcant effect of Fontaine stage on the outcome of theintervention. A similar pattern of gender difference with re-
gard to disease severity was also seen for the TASC II clas-
siﬁcation (Table II).
Treatment details. In 64 cases, femoral access was
gained during open arterial reconstructions. In two of these
(both men), a concomitant PTA of the superﬁcial femoral
artery was performed. In an additional 19 cases, stent-PTA
of the iliac artery was combined with an ipsilateral femoral
intervention (Table III).
There were no signiﬁcant differences concerning loca-
tion and extent of the treated lesions as well as type, num-
ber, and deployment modality of the devices. The only
exception was that more kissing stents were placed in
women (P ¼ .007). The average number of stents placed
was 1.24 in both groups (P ¼ .952; Table IV). Corre-
sponding to the smaller vessel calibers in women, diameters
Table III. Additional ipsilateral interventions
Variablea All (404 interventions) Women (128 interventions) Men (276 interventions) P
Total additional interventions 85 (21.0)b 23 (18.0) 62 (22.5)b .231
SFA PTA/stent 21 (5.2) 4 (3.1) 17 (6.2) .237
Femoral endarterectomy 40 (9.9) 11 (8.6) 29 (10.5) .596
Femoropopliteal bypass 20 (5.0) 6 (4.7) 14 (5.1) 1.000
Femorofemoral (crossover) bypass 4 (1.0) 2 (1.6) 2 (0.7) .594
PTA, Percutaneous transluminal angioplasty; SFA, superﬁcial femoral artery.
aVariables are given as total number (percentages).
bIn two men, femoral endarterectomy was performed with a concomitant PTA of the SFA (n ¼ 2).
Table IV. Distribution of the iliac lesions and stent characteristics
Variablea All (404 interventions) Women (128 interventions) Men (276 interventions) P
Bilateral intervention 134 (33.2) 50 (39.1) 84 (30.4) .090
Target vessel
CIA 211 (52.2) 72 (56.3) 139 (50.4) .286
Kissing stent 34 (8.4) 18 (14.1) 16 (5.8) .007
EIA 115 (28.5) 31 (24.2) 84 (30.4) .236
CIA/EIA 78 (19.3) 25 (19.5) 53 (19.2) 1.000
Occlusion type (n ¼ 399)
>60% stenosis 345 (86.5) 107 (83.6) 238 (86.2) .753
Occlusion 54 (13.5) 18 (14.1) 36 (13.0) .753
Number of stents 1.24 6 0.47 (1.0-3.0) 1.24 6 0.48 (1.0-3.0) 1.24 6 0.46 (1.0-3.0) .952
1 314 (77.7) 100 (78.1) 214 (77.5) 1.000
2 83 (20.5) 25 (19.5) 58 (21.0) .792
3 7 (1.7) 3 (2.3) 4 (1.5) .684
Stent type (n ¼ 390)
Steel 293 (72.5) 98 (76.6) 195 (70.7) .168
Nitinol 97 (24.0) 25 (19.5) 72 (26.1) .168
Deployment type (n ¼ 392)
Balloon expanded 80 (19.8) 20 (15.6) 60 (21.7) .178
Self-expanding 312 (77.2) 105 (82.0) 207 (75.0) .178
Dimension (n ¼ 399)
Length, mm 59.7 6 30.4 (15.0-180.0) 59.0 6 28.5 (15.0-145.0) 60.1 6 31.4 (15.0-180.0) .726
Maximum diameter, mm 8.6 6 1.3 (4.0-15.0) 8.1 6 1.4 (5.0-12.0) 8.8 6 1.2 (4.0-15.0) <.001
Minimum diameter, mm 8.3 6 1.3 (4.0-12.0) 7.8 6 1.4 (5.0-12.0) 8.5 6 1.2 (4.0-12.0) <.001
CIA, Common iliac artery; EIA, external iliac artery.
aData are expressed as mean 6 standard deviation (range) or number (%).
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(P < .001).
Postoperative medical treatment consisted of lifelong
antiplatelet monotherapy in 93.8% of cases, and 5.4%
received double antiplatelet treatment. Clopidogrel was
prescribed twice as often after the treatment of women
compared with men (10.2% vs 5.1%, respectively); however,
this difference was not statistically signiﬁcant (P ¼ .084).
Perioperative and early postoperative results
(<30 days). The technical success rate was high with a
revascularization rate of 97.7% in women and 99.3% in
men (Table V). One case of acute stent thrombosis was
treated by thrombolysis. In one patient, the lesion could
not be passed. In three other cases, signiﬁcant arterial wall
dissection was not manageable by an endovascular
approach; in these patients, open surgery was per-
formed. Clinically relevant puncture site bleeding (major
hematomas and pseudoaneurysms) at the arterial access site
occurred more often in women than in men (4.7% vs 0.4%and 8.6% vs 2.5%; P ¼ .005 and P ¼ .009, respectively). To
investigate additional risk factors for hematomas and
pseudoaneurysms, multivariate analysis was performed
including the variables age, gender, obesity, and minimal
stent diameter as a benchmark for iliofemoral vessel
diameter. Whereas age proved to be a second independent
risk factor for puncture site bleeding (P ¼ .019; hazard
ratio ¼ 1.53; 95% conﬁdence interval, 1.07-2.19), gender
remained the single most important risk factor (P ¼ .005;
hazard ratio ¼ 3.68; 95% conﬁdence interval, 1.48-9.13).
A target vessel rupture occurred in one case in each group
and was treated by stent graft insertion.
During early follow-up, one man died of myocardial
infarction. Three in-stent restenoses occurred and were
not treated in one asymptomatic patient; the remaining
two patients were treated by PTA or stent-PTA. In 10 cases
(four women, six men), early stent thrombosis was
observed and treated by thrombolysis in one case, stent-
PTA in seven cases, and open iliofemoral reconstruction
Table V. Outcome
Variablea All (404 interventions) Women (128 interventions) Men (276 interventions) P
Complications 51 (12.6)b 26 (20.3)b 25 (9.1) .002
Hematoma 7 (1.7) 6 (4.7) 1 (0.4) .005
Pseudoaneurysm 18 (4.5) 11 (8.6) 7 (2.5) .009
Dissection 12 (3.0) 5 (3.9) 7 (2.5) .531
Rupture 3 (0.7) 2 (1.6) 1 (0.4) .237
Embolization 4 (1.0) 2 (1.6) 2 (0.7) .594
Residual stenosis (50%-60%) 9 (2.2) 2 (1.6) 7 (2.5) .725
Primary success 399 (98.8) 125 (97.7) 274 (99.3) .332
Follow-up interval, months 45.0 6 33.3 (0.0-128.6) 45.6 6 30.6 (0.0-128.6) 45.2 6 34.5 (0.1-128.4) .902
Primary patency, months 39.3 6 32.4 (0.0-123.9) 42.1 6 31.1 (6.7-112.3) 38.0 6 33.0 (0.0-123.9) .229
Recurrence 89 (22.3) 33 (26.4) 56 (20.4) .306
Restenosis >60% 61 (15.3) 21 (16.8) 40 (14.6) .771
Occlusion 28 (7.0) 12 (9.6) 16 (5.8) .205
Early recurrence (<30 days)c 13 (3.3) 4 (3.2) 9 (3.3) 1.000
Secondary patency, months 44.1 6 32.8 (6.7-128.4) 46.8 6 30.6 (6.7-112.3) 42.8 6 33.8 (6.7-128.4) .250
Recurrence 29 (7.3) 8 (6.4) 21 (7.7) .836
Restenosis >60% 14 (3.5) 3 (2.4) 11 (4.0) .563
Occlusion 15 (3.8) 5 (4.0) 10 (3.6) 1.000
aBinary variables are given as total numbers and percentages; continuous variables are given as mean 6 standard deviation (range).
bIn two women, two complications occurred simultaneously: pseudoaneurysm and dissection (n ¼ 1); pseudoaneurysm and residual stenosis (n ¼ 1).
cIncludes early restenosis and occlusion <30 days.
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women and 96.7% in men; primary assisted patency was
100% in both groups. Within early follow-up, minor ampu-
tations were performed in three cases (two women; P ¼
.237) and major amputations in one case (man; P ¼ 1.00).
Univariate and multivariate analysis of risk factors
potentially affecting early results did not reveal any signiﬁ-
cant associations with regard to gender (data not shown).
Follow-up. On follow-up, all treated vessels were
investigated with duplex ultrasound. Twenty-four patients
(nine women) died during follow-up. Average follow-up
time was 45.6 6 30.6 months for interventions in
women and 45.2 6 34.5 months in men.
Signiﬁcant (>60%) late restenosis (>30 days) was
detected in 21 (16.8%) cases in women and in 40
(14.6%) cases in men (Table V). Restenosis was treated
by PTA in 19 (31.1%) and by stent-PTA in 26 (42.6%)
cases. In one patient, femoral endarterectomy with retro-
grade iliac thrombectomy was performed, and one patient
underwent open aortobifemoral reconstruction because of
multiple bilateral high-grade restenoses (two limbs). In
the remaining 13 cases (21.3%), restenosis was asymptom-
atic and therefore managed conservatively.
Late (>30 days) stent thrombosis occurred in 8 (6.4%)
cases in women and in 10 (3.6%) cases in men. Iliac arteries
were treated by PTA (n ¼ 3; 16.7%), stent-PTA (n ¼ 7;
38.9%), or open reconstruction (four iliofemoral, one aor-
tobifemoral [n ¼ 6; 33.3%]). One patient with bilateral
claudication opted for conservative treatment.
Primary patency rates at 1, 3, 5, and 7 years were 90.3%
(standard error [SE], 2.8), 77.2% (SE, 4.1), 60.2% (SE,
5.5), and 46.4% (SE, 6.6) and 89.9% (SE, 2.0), 71.5%
(SE, 3.2), 63.6% (SE, 3.6), and 59.7% (SE, 4.1) for women
and men, respectively (P ¼ .524; log-rank, .406). The
respective secondary patency rates were 97.2% (SE, 1.6),91% (SE, 2.9), 81.5% (SE, 4.5), and 70.3% (SE, 6.6) and
97.1% (SE, 1.1), 89.1% (SE, 2.2), 82.6% (SE, 3.0), and
78% (SE, 3.8) for women and men, respectively (P ¼
.959; log-rank, .003; Fig 1).
Univariate analysis of risk factors revealed lower age as
a predictor for decreased patency for both groups (P ¼
.002 and P ¼ .013, respectively). Continued smoking
(P ¼ .041) and minimum stent diameter (P ¼ .013) had
a signiﬁcant negative effect on long-term outcome in
men. Multivariate analysis identiﬁed lower age as the only
independent risk factor for stent occlusion or restenosis
for both groups (Table VI). In addition, the risk of stent
failure was signiﬁcantly lower with larger stent diameters
in men (P ¼ .013).
As a result, age-deﬁned subgroups were analyzed with
a cutoff at the median age of 63.5 years. The reocclusion/
restenosis rate was 23.9% in men and 22.1% in women for
the age of 63.5 years or older (P ¼ .861). For younger pa-
tients, however, the rate of reocclusion/restenosis was
32.1% in men (n ¼ 14) but 49.1% in women (n ¼ 57;
P ¼ .034). However, available follow-up intervals varied
signiﬁcantly between younger (54.7 6 33.0 months) and
older (36.2 6 31.0 months) patients (P < .001). Conse-
quently, Kaplan-Meier life-table analysis was performed
and showed a considerable but nonsigniﬁcant negative ef-
fect of young age on stent patency in women (P ¼ .166;
log-rank, 1.916; Figs 2 and 3).
DISCUSSION
The perception of cardiovascular disease has long
been that of being a typically “male” disease. This may
be associated with the fact that women are frequently un-
derrepresented in reports on the outcome of vascular sur-
gery procedures. However, the outcome of those
procedures is often signiﬁcantly different in women
Fig 1. Gender-speciﬁc cumulative primary and secondary patency
rates. n. at risk, numbers at risk. Black curves represent the female
study population; gray curves, the male study population. Inter-
rupted lines represent primary patency rates; solid lines, secondary
patency rates. Log-rank testing did not reveal signiﬁcant gender-
speciﬁc differences concerning either primary or secondary
patency rates.
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the short-term outcome after carotid revascularization in
women is less favorable11 and that women with abdominal
aortic aneurysms tend to be diagnosed at a later stage of
disease and have a worse short-term outcome.12 Lower
patency rates and worse survival have been reported for
women with PAOD.13 Women are often affected by an
increased number of complications after surgical and endo-
vascular procedures.14,15 In this study, the higher total
complication rate of 20.3% in women vs 9.1% in men
(P ¼ .003) was almost entirely due to an increased rate
of access site complications, including hematomas (4.7%
vs 0.4% in women and men, respectively) and pseudoa-
neurysms (8.6% vs 2.5%). Reasons may be the higher age
associated with possible agitation during intervention.
In this study, women were signiﬁcantly older, suffered
more often from hypertension, and presented with a more
severe stage of PAOD than men. It is a common ﬁnding in
the literature that women are older on ﬁrst presentation
and suffer from a more severe stage of disease as deﬁned
by a more complex pathologic process of their le-
sions.8,16,17 Surprisingly, despite the more adverse factorsbeing present in women, the overall long-term patency
was comparable between the genders. Even for the sub-
group of patients with the worst clinical parameters of
CLI and TASC type D lesions, these factors did not nega-
tively affect patency rates in men or women. However, pre-
viously published studies have delivered inconsistent results
concerning the inﬂuence of disease severity as assessed by
the TASC classiﬁcation and the patency of stents. Kudo
et al7 reported an increased risk for recurrent disease in pa-
tients after angioplasty with selective stenting of TASC II
type C and type D lesions compared with TASC type A le-
sions. In contrast, Sixt et al18 reported comparable primary
patency rates of 85% to 89% and secondary patency rates of
98% to 100% irrespective of TASC II lesion type after
endovascular treatment at 1 year.
Similarly, kissing stent deployment has previously been
associated with a higher risk of restenosis and reocclu-
sion.19,20 In our study, the higher frequency of kissing
stent deployment in women was not associated with a
decreased patency.
Whereas our overall primary patency rates are compara-
ble with existing data of mixed populations,9,11 our results
in women are clearly better than numbers published previ-
ously. In a study investigating patients with CLI, Timaran
et al8 found primary patency rates of 92%, 88%, and 88% for
men but only 79%, 57%, and 38% for women at 1, 3, and
5 years. The authors identiﬁed female gender as an inde-
pendent predictor of decreased stent patency. The lowest
patency rates were identiﬁed in women with angioplasty
and stenting, including EIA lesions, but one has to take
into account the small number of cases in that subgroup
analysis (36 stents including the EIA: 18 women, 18
men). In this study (including 115 EIA stents and 78 com-
bined common iliac artery/EIA stents), neither treatment
of the EIA nor smaller vessel diameters in women were sig-
niﬁcant risk factors for reduced primary patency rates.
However, we included patients with claudication and
with CLI. Furthermore, the rate of TASC type C and
type D lesions was clearly higher in the collective investi-
gated by Timaran et al: 46% in women compared with
22% in men, as opposed to 18% and 8.7%, respectively, in
this study.
On the basis of the multivariate analysis, lower age for
both genders and minimum stent diameter in men were
associated with a signiﬁcant negative effect on the outcome
after iliac artery stenting. A more virulent form of PAOD
might be a reason for the poorer outcome in our younger
patient group. Patients with premature PAOD do have the
traditional cardiovascular risk factors, but the course of
atherosclerosis is more aggressive than in older patients,
thus leading to an earlier and more severe development
of disease.21 Our ﬁnding of lower patency rates in younger
patients is in line with previously published data. Davis
et al22 found that patients requiring reinterventions were
more frequently of younger age, were of female gender,
and had a history of smoking. Yasuhara et al23 identiﬁed
younger age as an independent risk factor for poor
outcome after iliac artery balloon angioplasty. The
Table VI. Independent predictors of primary patency stratiﬁed by gender
Women Men
P Hazard ratio 95% Conﬁdence interval P Hazard ratio 95% Conﬁdence interval
Univariate analysis
Age (10 years) .002 0.648 0.495-0.848 .013 0.708 0.540-0.929
Ankle-brachial index (factor 0.1) .298 0.935 0.824-1.061 .674 0.978 0.879-1.087
TASC A/B vs C/D .149 1.813 0.808-4.069 .822 1.111 0.444-2.785
Fontaine stage II vs III/IV .813 0.912 0.425-1.958 .789 1123 0.480-2.625
Cardiovascular risk factors
Arterial hypertension .591 0.824 0.407-1.668 .134 0.672 0.400-1.131
Diabetes mellitus .230 0.557 0.214-1.447 .813 0.930 0.509-1.699
Hyperuricemia .452 0.046 0.000-139.561 .043 0.301 0.094-0.963
Obesity .965 0.981 0.425-2.266 .158 0.566 0.257-1.248
Current smoker .052 2.317 0.994-5.402 .041 1.905 1028-3.532
Current or previous smoker .116 2.047 0.838-5.003 .485 1.264 0.655-2.438
Postinterventional medication
Antiaggregation .486 21.735 0.004-124,414.028 .442 0.697 0.277-1.750
ASA .410 1.496 0.573-3.905 .821 0.921 0.452-1.878
Clopidogrel .435 0.564 0.134-2.372 .901 1.067 0.385-2.954
ASA þ clopidogrel .586 1.395 0.421-4.618 .855 0.876 0.214-3.594
Statin .035 2.106 1.054-4.206 .248 1.353 0.810-2.261
Treatment characteristics
Occlusion vs stenosis .566 1.302 0.529-3.205 .518 1.280 0.605-2.710
CIA only .481 0.781 0.394-1.551 .246 0.738 0.442-1.233
Stent material .952 0.973 0.397-2.382 .095 1.585 0.924-2.720
Deployment mode .878 1078 0.413-2.814 .127 1546 0.884-2.704
1 stent only .686 1.189 0.513-2.752 .975 0.990 0.524-1.871
Minimum stent diametera .404 0.667 0.257-1.729 .013 0.492 0.281-0.861
Length of treated segmenta .781 0.907 0.454-1.809 .801 0.936 0.561-1.562
Additional outﬂow procedure .272 1.601 0.691-3.707 .459 1.256 0.688-2.294
Multivariate analysis
Age (10 years) .002 0.648 0.495-0.848 .010 0.682 0.516-0.916
Minimum stent diameter .007 0.462 0.263-0.811
ASA, Acetylsalicylic acid; CIA, common iliac artery; TASC, TransAtlantic Inter-Society Consensus.
The following cardiovascular risk factors were entered into a multivariate Cox regression model and selected by forward stepwise selection: age, ankle-brachial
index, TASC II, critical ischemia, arterial hypertension, diabetes mellitus, hyperuricemia, smoking status (current smoker), postinterventional antiaggregation,
postinterventional statin use, preinterventional target vessel occlusion, treated vessel segment (CIA only), stent material, deployment mode, number of stents
used, minimum stent diameter (<median), length of treated segment (>median).
a(>Median).
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87%, and 80% for patients older than 60 years but 85%,
77%, and 57% for younger patients, respectively. Elderly
patients showed signiﬁcantly better results than the group
of younger patients (P ¼ .024). Siskin et al24 reviewed
the long-term outcome of 42 patients 50 years and
younger after iliac artery stent placement. They showed a
1-, 2-, and 3-year primary patency rate of 86%, 72%, and
65%, respectively, and a 3-year secondary patency rate of
88%. Despite successful stent placement with an initial
technical success of 95% and symptom relief in 76.2% of pa-
tients, the need for repeated interventions was 28.6%, even
though restenosis could mostly be treated with an endovas-
cular approach.
However, none of these authors has identiﬁed young
women as a group that has an exceptionally high risk of sig-
niﬁcant restenosis/reocclusion, whereas in our collective,
recurrence rates reached nearly 50% in women younger
than 63.5 years compared with 22% in the older popula-
tion. The fact that this was not statistically signiﬁcant ismost likely due to the shorter follow-up intervals in
younger patients.
Limitations of the study. This is a retrospective anal-
ysis of a single-center institution. Women were more likely
to undergo iliac artery stenting as opposed to open surgery,
which may have caused a bias in patient selection. In
addition, a higher number of male claudicants were
included. However, the proportion of women being
included was high, and patient and stent characteristics
were well balanced between genders. Patency was assessed
not only by clinical examination but also by imaging in all
cases. This accurately identiﬁed all restenoses and reoc-
clusions and not only symptomatic recurrences.
CONCLUSIONS
To unequivocally prove that young women have a
worse outcome compared with young men, a prospectively
conducted trial with comparable characteristics of patients
would be necessary. The fact that young and especially fe-
male patients have a higher life expectancy compared with
Fig 3. Age-dependent primary patency rates in women. n. at risk,
numbers at risk. Black curves represent patency in women younger
than 63.5 years; gray curves represent patency in women older than
63.5 years. Log-rank testing did not reveal signiﬁcant age-
dependent differences concerning primary patency rates.
Fig 2. Age-dependent primary patency rates in men. n. at risk,
numbers at risk. Black curves represent patency in men younger
than 63.5 years; gray curves represent patency in men older than
63.5 years. Log-rank testing did not reveal signiﬁcant age-
dependent differences concerning primary patency rates.
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patient cohort that has previously been identiﬁed as prob-
lematic. The use of drug-eluting balloons or stents would
certainly be a treatment approach that is worthwhile to
be tested in patients with an unfavorable biology of their
PAOD. In addition, surgical therapy must be considered
an alternative to stenting of aortoiliac disease in young
women who are good candidates for surgery. Which
approach proves to be best needs to be prospectively
addressed.
Our data show that although women are older and pre-
sent with a more advanced stage of PAOD, treatment with
an endovascular technique is equally effective irrespective
of gender. However, young female patients are at risk for
a less favorable outcome after iliac artery stenting, and
therefore this group of patients requires attention. Further
investigations are mandatory to develop risk-adapted treat-
ment strategies.
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